טוען...
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad spectrum of immune-related adverse events (irAEs). Immune-related myasthenia gravis (irMG) is a rare but life-threatening irAE....
שמור ב:
| הוצא לאור ב: | Front Neurol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7378376/ https://ncbi.nlm.nih.gov/pubmed/32765397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00634 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|